Precision Medicine in Thoracic Oncology: Targeted Therapies and Personalized Treatment Strategies

Landelle Caroline^*
*Correspondence: Landelle Caroline, Department of Respiratory Diseases, Monash University, Clayton, Victoria, Australia, Email:

Keywords

Thoracic oncology • Lung cancer • Carcinoma

Introduction

Lung cancer is the most common form of thoracic malignancy and is a leading cause of cancer-related deaths worldwide. It is broadly categorized into two main types: Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). NSCLC comprises the majority of lung cancer cases and includes subtypes such as adenocarcinoma, squamous cell carcinoma and large cell carcinoma. SCLC is a less common but highly aggressive form of lung cancer. The causes of thoracic malignancies, particularly lung cancer, are multifactorial [1]. The most significant risk factor is tobacco smoking, accounting for the majority of cases. Other risk factors include exposure to second-hand smoke, occupational exposure to carcinogens (such as asbestos, radon and certain chemicals), genetic predisposition and environmental factors.

Traditionally, cancer treatment has followed a one-size-fits-all approach, where patients with similar diagnoses received similar treatment regimens. However, precision medicine recognizes that each patient's tumor has unique characteristics, driven by genetic and molecular alterations. It seeks to identify these alterations and tailor treatment strategies accordingly, leading to improved outcomes and reduced side effects [2]. One of the cornerstones of precision medicine in thoracic oncology is genomic profiling. By analyzing the tumor's DNA, researchers can identify specific genetic mutations or alterations that drive the cancer's growth. This knowledge allows clinicians to select targeted therapies that directly address the underlying molecular abnormalities.

Description

In lung cancer, for instance, certain genetic alterations such as Epidermal Growth Factor Receptor (EGFR) mutations, Anaplastic Lymphoma Kinase (ALK) rearrangements and ROS1 fusions have been identified as key drivers of tumor growth. Targeted therapies, such as EGFR inhibitors (e.g., erlotinib, osimertinib), ALK inhibitors (e.g., crizotinib, alectinib) and ROS1 inhibitors (e.g., crizotinib), have demonstrated remarkable efficacy in patients with these specific alterations. These drugs inhibit the activity of the mutated proteins, leading to tumor regression and prolonged survival. In addition to targeted therapies, precision medicine has also significantly advanced the field of immunotherapy [3]. Immune checkpoint inhibitors, such as pembrolizumab and nivolumab, have revolutionized the treatment landscape for thoracic cancers. These drugs unleash the patient's immune system to recognize and attack cancer cells.

To optimize the use of immunotherapies, biomarkers like Programmed Death-ligand 1 (PD-L1) expression and Tumor Mutational Burden (TMB) are used to identify patients who are most likely to benefit from these treatments. PD-L1 expression levels help determine the likelihood of response to immune checkpoint inhibitors, while TMB provides an estimate of the number of mutations in a tumor, which can correlate with increased immunogenicity and response to immunotherapy. Precision medicine goes beyond targeting specific genetic alterations or utilizing immunotherapies. It involves a comprehensive understanding of the patient's clinical, genetic and lifestyle factors to develop personalized treatment strategies [4]. This may involve combining targeted therapies with conventional treatments like chemotherapy or radiation therapy, or integrating complementary therapies to improve overall patient outcomes.

Furthermore, advancements in liquid biopsies, which involve analyzing circulating tumor DNA, allow for real-time monitoring of treatment response and the identification of emerging resistance mechanisms. This enables clinicians to adapt treatment strategies promptly, providing patients with the best chance for successful outcomes. While precision medicine has brought about a paradigm shift in thoracic oncology, several challenges still exist. Limited access to comprehensive genomic profiling, the high cost of targeted therapies and the need for reliable biomarkers are among the barriers that need to be addressed. Additionally, the emergence of acquired resistance to targeted therapies remains a significant concern, necessitating the development of novel treatment strategies and the identification of resistance mechanisms.

Immunotherapy, particularly immune checkpoint inhibitors, has also emerged as a breakthrough in the treatment of thoracic cancers. These drugs help the immune system recognize and attack cancer cells, leading to durable responses and improved survival rates in certain patients [5]. Looking ahead, the integration of artificial intelligence and machine learning algorithms will play a pivotal role in deciphering complex genomic data, predicting treatment responses and optimizing treatment selection. Collaborative research efforts and data sharing initiatives will also be crucial in expanding our understanding of thoracic malignancies and refining personalized treatment approaches.

Conclusion

Precision medicine has transformed the landscape of thoracic oncology, offering new hope to patients with previously limited treatment options. The identification of genetic alterations, targeted therapies and personalized treatment strategies have significantly improved outcomes in lung cancer and other thoracic malignancies. However, there is still much to learn and accomplish. By embracing the principles of precision medicine, healthcare professionals and researchers can continue to advance our understanding and treatment of thoracic cancers, bringing us closer to a future where these diseases can be effectively managed and ultimately, conquered. With the advent of precision medicine and targeted therapies, significant progress has been made in improving treatment outcomes for patients with thoracic malignancies. Continued research, technological advancements and collaboration among healthcare professionals hold promise for further advancements in the field, ultimately leading to better outcomes and a higher quality of life for individuals affected by thoracic cancers.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Qian, Mengjia, Qian Li, Miaomiao Zhang and Xiaojing Xu, et al. "Multidisciplinary therapy strategy of precision medicine in clinical practice." Clin Transl Med 10 (2020): 116-124.

Google Scholar, Crossref, Indexed at

2. Dagogo-Jack, Ibiayi and Jochen K. Lennerz. "Personalized diagnostic workflows: The next wave of precision medicine in NSCLC." J Thorac Oncol 15 (2020): 888-890.

Google Scholar, Crossref, Indexed at

3. Janiaud, Perrine, Stylianos Serghiou and John PA Ioannidis. "New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses and current use in oncology." Cancer Treat Rev 73 (2019): 20-30.

Google Scholar, Crossref, Indexed at

4. Genova, Carlo. "The long run towards personalized therapy in non-small-cell lung cancer: Current state and future directions." Int J Mol Sci 24 (2023): 8212.

Google Scholar, Crossref, Indexed at

5. Hirsch, Fred R., Giorgio V. Scagliotti, James L. Mulshine and Regina Kwon, et al. "Lung cancer: Current therapies and new targeted treatments." Lancet 389 (2017): 299-311.

Google Scholar, Crossref, Indexed at